ABOUT ELIDEL (PIMECROLIMUS) CREAM, 1%

ELIDEL (pimecrolimus) Cream, 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable.6

If a first-line therapy is either inappropriate or ineffective in managing eczema, ELIDEL Cream can help treat mild to moderate flares.6


Important Safety Considerations:

The safety of ELIDEL has not been established beyond one year of non-continuous use. Application should be limited to areas of involvement with atopic dermatitis (see Boxed Warning below).


Eczema Treatment Goals

  • Reducing the signs and symptoms of eczema (including pruritus).4
  • Reducing the severity and frequency of flares.4

See How ELIDEL Cream Works

See Systemic Absorption of ELIDEL

See More

INDICATION

ELIDEL® (pimecrolimus) Cream 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable.


IMPORTANT SAFETY INFORMATION

WARNING:

Long-term Safety of Topical Calcineurin Inhibitors Has Not Been Established. Although a causal relationship has not been established, rare cases of malignancy (e.g., skin and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including ELIDEL Cream.